The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
General Updates | The potential of the six-minute walk test as a prognostic tool in patients with sickle cell disease
In this video, Payal Desai, MD, Levine Cancer Institute & Wake Forest School of Medicine, Charlotte, NC, discusses the potential use of the six-minute walk distance test as a prognostic tool in patients with sickle cell disease (SCD). In an analysis of data from the STERIO-SCD (NCT02633397) trial, the six-minute walk distance was associated with high-risk criteria, suggesting that it could be used as a non-invasive method to identify patients at greater risk of exhibiting disease-related complications. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we looked at the data from, it was a very large study called the STERIO-SCD study that looked at the impact of riociguat in patients and if it made a difference in terms of their pulmonary pressures, blood pressure, and we measured outcomes like six minute walk test and things. So that was published in The Lancet, and it was a very large group of multidisciplinary researchers that worked on that study...
So we looked at the data from, it was a very large study called the STERIO-SCD study that looked at the impact of riociguat in patients and if it made a difference in terms of their pulmonary pressures, blood pressure, and we measured outcomes like six minute walk test and things. So that was published in The Lancet, and it was a very large group of multidisciplinary researchers that worked on that study. So, based on some of that data and what we saw in the baseline data, we wanted to ask the question… some of the screening criteria were if people had nephropathy or if people had high blood pressure, so those were considered high-risk criteria because there’s been some prior associations with those patients having pulmonary hypertension, so we wanted to see if that made a difference in their baseline six minute walk test.
And we did see a difference. So if for example, you had one high risk criteria, your pulmonary hypertension or your six minute walk test was a certain amount, and then if you had two risks, it got lower, and if you had three risks, it was much lower. And so we did see an association with these high risk criteria and baseline six minute walk test. And we went on to look at a few other things, including their oxygenation and things, and again, those high risk criteria correlated with those as well at baseline. And so we were wondering… and even their proteinuria got worse as their high risk criteria and those six minute walk test got worse.
So the question becomes could you potentially use some of these. It’s a very low resource intervention, evaluation. It doesn’t require blood. It doesn’t require anything. It just requires the patient to walk and a pulse oximeter. So could you use something that is very low resource intensity to be predictive of some of these other issues developing? And then if you had enough data, maybe even as a screening criteria.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
